DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Kyung Hwan | ko |
dc.contributor.author | Hur, Joon Young | ko |
dc.contributor.author | Cho, Jinhyun | ko |
dc.contributor.author | Ku, Bo Mi | ko |
dc.contributor.author | Koh, Jiae | ko |
dc.contributor.author | Koh, June Young | ko |
dc.contributor.author | Sun, Jong-Mu | ko |
dc.contributor.author | Lee, Se-Noon | ko |
dc.contributor.author | Ahn, Jin Seok | ko |
dc.contributor.author | Park, Keunchil | ko |
dc.contributor.author | Ahn, Myung-Ju | ko |
dc.contributor.author | Shin, Eui-Cheol | ko |
dc.date.accessioned | 2020-03-19T02:20:38Z | - |
dc.date.available | 2020-03-19T02:20:38Z | - |
dc.date.created | 2020-02-18 | - |
dc.date.created | 2020-02-18 | - |
dc.date.issued | 2020-01 | - |
dc.identifier.citation | ONCOIMMUNOLOGY, v.9, no.1 | - |
dc.identifier.issn | 2162-402X | - |
dc.identifier.uri | http://hdl.handle.net/10203/272581 | - |
dc.description.abstract | Although anti-programmed death-1 (PD-1) treatment has shown remarkable anti-tumor efficacy, immune-related adverse events (irAEs) develop with heterogeneous clinical manifestations. However, the immunological understanding of irAEs is currently limited. In the present study, we analyzed peripheral blood T cells obtained from cancer patients who received anti-PD-1 treatment to determine the immunological characteristics of irAEs. This study included 31 patients with refractory thymic epithelial tumor (TET) who were enrolled in a phase II trial of pembrolizumab (NCT02607631) and 60 patients with metastatic non-small cell lung cancer (NSCLC) who received pembrolizumab or nivolumab. T-cell profiling was performed by multicolor flow cytometry using peripheral blood obtained before treatment and 7 days after the first dose of anti-PD-1 antibodies. irAEs developed in 21 TET patients and 24 NSCLC patients. Severe (>= grade 3) irAEs occurred in 7 TET patients (22.6%) and 6 NSCLC patients (10.0%). Patients with severe irAEs exhibited a significantly lower fold increase in the frequency of effector regulatory T (eTreg) cells after anti-PD-1 treatment, a higher ratio of T helper-17 (Th17) and T helper-1 cells at baseline, and a higher percentage of Ki-67(+) cells among PD-1(+)CD8(+) T cells posttreatment. In clustering analysis using the T-cell parameters, patients with irAEs were grouped into four distinct subtypes: Th17-related, TNF-related, CD8-related Treg-compensated, and CD8-related Treg-uncompensated. The T-cell parameters showed a predictive value for the development of each subtype of severe irAEs. In conclusion, severe irAEs after anti-PD-1 treatment were clustered into four immunological subtypes, and potential biomarkers for early prediction of severe irAEs were proposed. | - |
dc.language | English | - |
dc.publisher | TAYLOR & FRANCIS INC | - |
dc.title | Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment | - |
dc.type | Article | - |
dc.identifier.wosid | 000510456800001 | - |
dc.identifier.scopusid | 2-s2.0-85079148823 | - |
dc.type.rims | ART | - |
dc.citation.volume | 9 | - |
dc.citation.issue | 1 | - |
dc.citation.publicationname | ONCOIMMUNOLOGY | - |
dc.identifier.doi | 10.1080/2162402X.2020.1722023 | - |
dc.contributor.localauthor | Shin, Eui-Cheol | - |
dc.contributor.nonIdAuthor | Hur, Joon Young | - |
dc.contributor.nonIdAuthor | Cho, Jinhyun | - |
dc.contributor.nonIdAuthor | Ku, Bo Mi | - |
dc.contributor.nonIdAuthor | Koh, Jiae | - |
dc.contributor.nonIdAuthor | Sun, Jong-Mu | - |
dc.contributor.nonIdAuthor | Lee, Se-Noon | - |
dc.contributor.nonIdAuthor | Ahn, Jin Seok | - |
dc.contributor.nonIdAuthor | Park, Keunchil | - |
dc.contributor.nonIdAuthor | Ahn, Myung-Ju | - |
dc.description.isOpenAccess | Y | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | Immune-related adverse event | - |
dc.subject.keywordAuthor | anti-PD-1 | - |
dc.subject.keywordAuthor | peripheral blood | - |
dc.subject.keywordAuthor | T cell | - |
dc.subject.keywordAuthor | immune profiling | - |
dc.subject.keywordAuthor | cancer | - |
dc.subject.keywordPlus | SECUKINUMAB | - |
dc.subject.keywordPlus | NIVOLUMAB | - |
dc.subject.keywordPlus | INTERLEUKIN-17A | - |
dc.subject.keywordPlus | ASSOCIATION | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.